JUSTTHENEWS (Misty Severi) - American Medical Association releases independent COVID, flu vaccine recommendations
The two medical groups released evidence reviews for the vaccines targeting COVID-19, respiratory syncytial virus (RSV) and the flu.
The two medical groups released evidence reviews for the vaccines targeting COVID-19, respiratory syncytial virus (RSV) and the flu.
"These corporations have learned how to play the medical-scientific establishment like a Stradivarius," Johns Hopkins cardiology operations chief says after Moderna share price spikes. Its mRNA flu vaccine trial data are still hidden.
The Food and Drug Administration (FDA) has approved Moderna's mRNA-based seasonal flu vaccine.
The Food and Drug Administration (FDA) has granted approval for Moderna’s mRNA-based flu vaccine for adults 50 and older, despite earlier regulatory concerns. PULSE POINTS WHAT HAPPENED: The Food and Drug Administration (FDA) has approved Moderna’s mRNA-based seasonal flu vaccine . DETAIL: Named mFLUSIVA, the vaccine was approved on Wednesday. It is aimed at people aged 50 and older. The decision comes after the FDA initially declined to approve the vaccine back in February. Specifically, the vaccine was initially blocked as the clinical trial did not use the best available comparator for adults aged 65 and older. “We are grateful to the clinical trial participants, investigators, regulators and Moderna teams whose…Open
The first mRNA-based flu shot to be approved by the Food and Drug Administration will be ready for the upcoming flu season. Moderna, the vaccine's maker
The first mRNA-based flu shot to be approved by the Food and Drug Administration will be ready for the upcoming flu season. Moderna, the vaccine's makerOpen
The agency approved the shot for two separate age groups: People age 50 to 64, and for 65 years and older.
Plus, what happens when you have an A.I. boss.
The Food and Drug Administration approved Moderna's mRNA seasonal flu vaccine on Wednesday.
The agency had initially refused to even review the application but reversed course after a public outcry.
The U.S. Army's missile stockpile is dwindling and could take years to replenish. And, the Food and Drug Administration is deciding whether to approve a flu vaccine with mRNA technology.
The U.S. Army's missile stockpile is dwindling and could take years to replenish. And, the Food and Drug Administration is deciding whether to approve a flu vaccine with mRNA technology.Open
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.Open